JAGUAR HEALTH, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
JAGUAR HEALTH, INC. (JAGX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $490.10 thousand for the 3-month period ending 2017-03-31, per its 10-Q/A filed 2017-06-23.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-06-23
- JAGUAR HEALTH, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $490.10K, a 426.89% increase year-over-year.
- JAGUAR HEALTH, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $477.29K, a 68.18% decline year-over-year.
- JAGUAR HEALTH, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $149.78K.
- JAGUAR HEALTH, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $1.66M.
- JAGUAR HEALTH, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $2.38M.
- JAGUAR HEALTH, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$3.00M.
- JAGUAR HEALTH, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$55.15K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | $490.10K 10-Q/A · filed 2017-06-23 | $967.39K derived: sum of 2 quarters · filed 2017-06-23 | $1.12M derived: sum of 3 quarters · filed 2017-06-23 | $2.78M derived: sum of 4 quarters · filed 2017-06-23 |
| 2016-12-31 | $477.29K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $627.06K derived: sum of 2 quarters · filed 2017-02-15 | $2.29M derived: sum of 3 quarters · filed 2017-02-15 | $2.38M 10-K · filed 2017-02-15 |
| 2016-09-30 | $149.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $1.81M derived: sum of 2 quarters · filed 2016-11-14 | $1.91M 10-Q · filed 2016-11-14 | $3.41M derived: sum of 4 quarters · filed 2017-06-23 |
| 2016-06-30 | $1.66M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2016-08-15 | $1.76M 10-Q · filed 2016-08-15 | $3.26M derived: sum of 3 quarters · filed 2017-06-23 | |
| 2016-03-31 | $93.02K 10-Q/A · filed 2017-06-23 | $1.59M derived: sum of 2 quarters · filed 2017-06-23 | ||
| 2015-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | -$3.00M 10-K · filed 2017-02-15 | ||
| 2015-09-30 | -$4.50M 10-Q · filed 2016-11-14 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | $0.00 derived: sum of 2 quarters · filed 2016-03-29 | -$55.15K 10-K · filed 2016-03-29 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | -$55.15K 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | -$55.15K 10-Q · filed 2015-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |